Abdulrahman Nasiri։ Decade of Evidence Supports ASCT2 in Relapsed Multiple Myeloma
Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared Mostafa Faisal Mohammed Saleh’s post on LinkedIn, adding:
”Honored to contribute to this review published in Current Oncology MDPI, evaluating a decade of evidence on second or salvage autologous stem cell transplantation in relapsed multiple myeloma.
This work reinforces that ASCT2 remains a clinically meaningful, risk-adapted option for selected patients, particularly those with prolonged first remission and chemosensitive relapse, even in the era of CAR-T and bispecific antibodies.
Grateful to collaborate with distinguished colleagues Marwa Nassar, Nourah Alzaidy, Amr Hanbali, Mahmoud Aljurf, and Mostafa Faisal Mohammed Saleh.
It was a privilege to work together on this important analysis.”
Mostafa Faisal Mohammed Saleh, Associate professor of Clinical Hematology and HSCT at Assiut University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
”Our recent review just out in Current Oncology: ASCT2 in relapsed MM (2016 – 2026) across14 key studies.
Feasible and safe: NRM 1–4% (day 100–1y) across large registries (n=305–975).
Median PFS 9.8–30.2 mo; OS ~30 to >80 mo depending on risk.
Interval ≥24 mo from ASCT1 = strongest predictor → PFS 17–45 mo; OS >60–80 mo in favorable subsets.
Maintenance matters: lenalidomide PFS 41 vs 21.6 mo; carfilzomib-dex TTP 25.1 vs 16.7 mo.
Phase III GMMG ReLApsE: no PFS/OS superiority (20.5 vs 19.3 mo; OS 67.1 vs 62.7) → selection is key.
In the CAR-T/bispecific era, ASCT2 = risk-adapted consolidation or bridge — not routine salvage.”
Title: Salvage or Second Autologous SCT in Relapsed Multiple Myeloma (2016–2026): A Decade in Review
Authors: Marwa Nassar, Nourah Alzaidy, Abdulrahman Nasiri, Amr Hanbali, Mahmoud A. Aljurf, Mostafa F. Mohammed Saleh
Read the Full Article on Current Oncology․
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 21, 2026, 21:07Tareq Abadl: Not Every Low Platelet Count Is True – Check the Smear First
-
Apr 21, 2026, 21:05Beverley Hunt: Honored to Receive the Lifetime Achievement Award at BSH 2026
-
Apr 21, 2026, 21:03Toong Youttananukorn: Proud to Support Data That Drives Action at WFH 2026
-
Apr 21, 2026, 20:48Ney Carter Borges: Endothelial Senescence as a Central Driver of Adipose Dysfunction in Heart Failure and Type 2 Diabetes
-
Apr 21, 2026, 20:29Can Stem Cell-Delivered Platelets Fight Drug-Resistant Bacteria?- RPTH Journal
-
Apr 21, 2026, 18:51WHO Expert Lorenzo Moja Discusses How Essential Medicines Policy Expands Access to Treatment – WFH
-
Apr 21, 2026, 18:35Ana Pedrero Gil: New ASH–ISTH 2026 Guidelines Focus on Preventing VTE in Children
-
Apr 21, 2026, 17:36Sip Wijchers: Is It Time to Use Ultrasound for Every AF Ablation Access?
-
Apr 21, 2026, 16:32Sarah Walbolt։ Have You Ever Wondered What Actually Happens to Your Donated Blood?